Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue$153.76M$153.76M+0.8% vs Q1 2022 Net Income$16.95M$16.95M−33.8% vs Q1 2022 EPS Diluted$0.29$0.29−32.6% vs Q1 2022 Operating Income$5,176,000+163.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
Free Cash Flowderived$48,848,000+1,315.5% Margins · derivedOperating margin3.4%+2.1 pt vs Q1 2022
Net margin11.0%−5.8 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end